Atox Bio, an Israeli based therapeutics developer for severe infections won a $24 million contract from the Biomedical Advanced Research and Development Authority to work on treatment of flesh-eating bacteria. The contract is for AB103, to treat necrotising soft tissue infections, better known as “flesh eating bacteria”, and potentially, infections caused by biothreats and public health threats that end in sepsis. AB103, is an immunomodulator licensed from Yissum, the technology transfer company of The Hebrew University in Jerusalem. It is a peptide that provides a different approach in treating infectious diseases by moderating, but not hindering, the host immune system.